Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood blood.2024024582.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells

Blood (2022) 140 (Supplement 1): 4688–4690.

https://doi.org/10.1182/blood-2022-168071

Published: 2022

Journal Articles

High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma

Ricardo Villanueva, Doris K. Hansen, Rolf Petter Tonseth, Kenneth L Gage, Zhouping Wei, Gabriel De Avila, Rachid C. Baz, Ariel F Grajales-Cruz, Omar Castaneda-Puglianini, Brandon J. Blue, Jason Brayer, Kenneth H. Shain, Melissa Alsina, Hien D. Liu, Taiga Nishihori, Meghan A Menges, Frederick L. Locke, Yoganand Balagurunathan, Ciara L. Freeman

Blood (2022) 140 (Supplement 1): 10402–10404.

https://doi.org/10.1182/blood-2022-167804

Published: 2022

Journal Articles

Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience

Blood (2022) 140 (Supplement 1): 4642–4645.

https://doi.org/10.1182/blood-2022-164828

Published: 2022

Journal Articles

Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient's Monitoring after CAR T-Cell Therapy

Omar Alexis Castaneda Puglianini, Lauren C. Peres, Doris K. Hansen, Taiga Nishihori, Ariel F Grajales-Cruz, Brandon J. Blue, Jason Brayer, Ciara L. Freeman, Kenneth H. Shain, Hien D. Liu, Jose Ochoa, Frederick L. Locke, Rachid C. Baz, Melissa Alsina

Blood (2022) 140 (Supplement 1): 7538–7539.

https://doi.org/10.1182/blood-2022-170135

Published: 2022

Journal Articles

A Multiomic Approach to Reversing Therapy Resistance in Multiple Myeloma Using Paired Ex Vivo Drug Sensitivity Measures and RNA Sequencing Data

Praneeth Reddy Sudalagunta, Mark B. Meads, Rafael Renatino-Canevarolo, Maria L. Coelho Siqueira Silva, Xiaohong Zhao, Rhett Waldron, Christopher Cubitt, Raghunandan Reddy Alugubelli, Gabriel De Avila, Oliver Hampton, Robert Gatenby, Rachid C. Baz, Kenneth H. Shain, Ariosto Siqueira Silva

Blood (2022) 140 (Supplement 1): 4245–4246.

https://doi.org/10.1182/blood-2022-162454

Published: 2022

Journal Articles

Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma

Cesar Rodriguez, Katja Weisel, Rachid C. Baz, Akshanth R. Polepally, Jeremy A. Ross, Ziyi Jin, Kristin D'Amico, Orlando F. Bueno, Leanne Lash Fleming, Peter M. Voorhees

Blood (2022) 140 (Supplement 1): 7326–7327.

https://doi.org/10.1182/blood-2022-157977

Published: 2022

Journal Articles

Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience

Taiga Nishihori, Ciara L. Freeman, Doris K. Hansen, Brandon J. Blue, Omar Alexis Castaneda Puglianini, Jongphil Kim, Ariel F. Grajales-Cruz, Jason Brayer, Jose Ochoa, Hien D. Liu, Kenneth H. Shain, Rachid C. Baz, Frederick L. Locke, Melissa Alsina

Blood (2022) 140 (Supplement 1): 4856–4858.

https://doi.org/10.1182/blood-2022-168888

Published: 2022

Journal Articles

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

Blood (2022) 140 (Supplement 1): 10427–10429.

https://doi.org/10.1182/blood-2022-163464

Published: 2022

Journal Articles

Multiple Myeloma Evolution Is Characterized By Dynamic Epigenetic Landscapes

Rafael Renatino-Canevarolo, Mark B. Meads, Maria L. Coelho Siqueira Silva, Praneeth Reddy Sudalagunta, Christopher Cubitt, Gabriel De Avila, Raghunandan Reddy Alugubelli, Amit Kulkarni, Qi Zhang, Oliver Hampton, Rachid C. Baz, Kenneth H. Shain, Ariosto Siqueira Silva

Blood (2022) 140 (Supplement 1): 3036–3037.

https://doi.org/10.1182/blood-2022-163511

Published: 2022

Journal Articles

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, Hang Quach, Rachid C. Baz, Annette Juul Vangsted, Shir-Jing Ho, Simon J Harrison, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Muhammad Jalaluddin, Jeremy A. Ross, Leanne Lash Fleming, Yan Luo, Nizar Jacques Bahlis

Blood (2022) 140 (Supplement 1): 7261–7263.

https://doi.org/10.1182/blood-2022-163809

Published: 2022

Journal Articles

Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma

Taiga Nishihori, Doris K. Hansen, Hien D. Liu, Omar Alexis Castaneda Puglianini, Ciara L. Freeman, Brandon J. Blue, Jason Brayer, Jongphil Kim, Ariel F Grajales-Cruz, Jose Ochoa, Rachid C. Baz, Kenneth H. Shain, Frederick L. Locke, Melissa Alsina

Blood (2022) 140 (Supplement 1): 5174–5176.

https://doi.org/10.1182/blood-2022-171117

Published: 2022

Journal Articles

A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Wilson I. Gonsalves, Natalia Neparidze, Jacob B. Allred, Shaji K Kumar, Joel M. Reid, Geoffrey Shapiro, Brian A. Costello, Richard Piekarz, Rachid C. Baz, Srinivas Devarakonda

Blood (2022) 140 (Supplement 1): 7315–7316.

https://doi.org/10.1182/blood-2022-164966

Published: 2022

Journal Articles

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Interim Analysis of Phase II Study

Rachid C. Baz, Jongphil Kim, Christine Sam, Brandon J. Blue, Sonila Toska, Aaron Collier, Jason Brayer, Ariel F Grajales-Cruz, Melissa Alsina, Ariosto Siqueira Silva, Kenneth H. Shain

Blood (2022) 140 (Supplement 1): 7313–7314.

https://doi.org/10.1182/blood-2022-159164

Published: 2022

Journal Articles

KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma

Michel Delforge, MDPhD, Rachid C. Baz, MD, Michele Cavo, Natalie S. Callander, MD, Armin Ghobadi, MD, Paula Rodriguez-Otero, MD PhD, María-Victoria Mateos, MD PhD, Monica Massaro, MPH, Li Ding, Payal Patel, Gianfranco Pittari, MD PhD, Steven Novick, MDPhD, Sergio A. Giralt, MD, Jesus G. Berdeja, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-137156

Published: 2020

Journal Articles

Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma

Shaji K. Kumar, MD, Rachid C. Baz, MD, Robert Z. Orlowski, MDPhD, Larry D. Anderson, Jr., MD PhD, Hong Ma, MD, Alexandria Shrewsbury, MS, Katrina A. Croghan, M.S., Mrinalini Bilgi, MS, Ankit Kansagra, MD, Prashant Kapoor, MD, Zonghai Li, MD PhD, Jason Brayer, PhDMD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-139802

Published: 2020

Journal Articles

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

Rachid C. Baz, Thomas G. Martin, III, Hui-Yi Lin, Xiuhua Zhao, Kenneth H. Shain, Hearn J. Cho, Jeffrey L. Wolf, Anuj Mahindra, Ajai Chari, Daniel M. Sullivan, Lisa A. Nardelli, Kenneth Lau, Melissa Alsina, Sundar Jagannath

Blood (2016) 127 (21): 2561–2568.

https://doi.org/10.1182/blood-2015-11-682518

Published: 2016

Includes: Supplemental data

Journal Articles

Aggressive Electrolytes Replacement in Multiple Myeloma (MM) Patients Receiving Arsenic Trioxide (ATO) Containing Regimens Alleviates the Need for Frequent Electrocardiogram (ECG) Monitoring.

Toni K. Choueiri, MD, Esteban Walker, PhD, Rachid C. Baz, MD, Rony M. Abou-Jawde, MD, Snehal G. Thakkar, MD, Bridget McGowan, Megan Kelly, Steven Andresen, MD, Mohamad Hussein, MD

Blood (2005) 106 (11): 5155.

https://doi.org/10.1182/blood.V106.11.5155.5155

Published: 2005

NARROW

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells

High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma

Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience

Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient's Monitoring after CAR T-Cell Therapy

A Multiomic Approach to Reversing Therapy Resistance in Multiple Myeloma Using Paired Ex Vivo Drug Sensitivity Measures and RNA Sequencing Data

Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma

Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

Multiple Myeloma Evolution Is Characterized By Dynamic Epigenetic Landscapes

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma

A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Interim Analysis of Phase II Study

KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma

Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

Aggressive Electrolytes Replacement in Multiple Myeloma (MM) Patients Receiving Arsenic Trioxide (ATO) Containing Regimens Alleviates the Need for Frequent Electrocardiogram (ECG) Monitoring.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only